Ghost Tree Capital’s Viking Therapeutics VKTX Stock Holding History

Ghost Tree Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$8.86M	Buy	140,000 +45,000	+47%	+$2.64M	2.68%	12
2024 Q2	$5.04M	Buy	95,000 +21,998	+30%	+$1.44M	1.58%	26
2024 Q1	$5.99M	Buy	+73,002	New	+$3.25M	1.66%	21
2023 Q4	–	Sell	-225,000	Closed	-$2.49M	–	75
2023 Q3	$2.49M	Sell	225,000 -425,000	-65%	-$6.08M	0.82%	43
2023 Q2	$10.5M	Buy	650,000 +50,000	+8%	+$1.05M	3.48%	10
2023 Q1	$9.99M	Buy	600,000 +300,000	+100%	+$3.1M	2.95%	10
2022 Q4	$2.82M	Buy	+300,000	New	+$1.34M	1.2%	24

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Ghost Tree Capital's VKTX Position: Q3 2024 in Review

Ghost Tree Capital increased its Viking Therapeutics (VKTX) stake by 47% in Q3 2024, buying an estimated $2.64M and bringing the position to 140,000 shares worth $8.86M. The position accounts for 2.68% of the portfolio, ranked #12.

Ghost Tree Capital first reported a position in VKTX in Q4 2022 and has held it in 7 quarters since. The position peaked at $10.5M in Q2 2023. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

Ghost Tree Capital held 140,000 shares of Viking Therapeutics worth $8.86M as of Q3 2024.
Ghost Tree Capital bought 45,000 Viking Therapeutics shares in Q3 2024, an estimated $2.64M.
Viking Therapeutics made up 2.68% of Ghost Tree Capital's portfolio in Q3 2024, its #12 holding.
Ghost Tree Capital first reported a position in Viking Therapeutics in Q4 2022 and has held it in 7 quarters since.
Ghost Tree Capital's Viking Therapeutics position peaked at $10.5M in Q2 2023.
422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.